New research is inspiring new ways of thinking about clinical coliform mastitis treatment decisions. In the past, dairy producers have tended to believe that antibiotic treatment is not effective for these infections. But a groundbreaking Cornell University study is the first to show a significant improvement in mild or moderate Gram-negative mastitis infections as a result of specific antibiotic therapy. Hear about the new research:
Highlights from the study: • Extended duration of therapy makes the difference: Five-day treatment with SPECTRAMAST® LC (ceftiofur hydrochloride) Sterile Suspension resulted in an 89 percent bacteriological, or complete, cure rate in mild or moderate mastitis caused by Escherichia coli (E. coli) compared with a cure rate of 53 percent for untreated controls. • More milk: Cows that were completely cured gave 8.8 more pounds of milk on the second test day when compared with cows that were not cured. (P<0.05) Visit to hear Ynte Schukken, DVM, Cornell University, and Roger Saltman, DVM, Pfizer Animal Health, discuss what the study means for treatment protocols, including the importance of culturing. Important Safety Information: Inappropriate dosage or treatment intervals for SPECTRAMAST LC or failure to adhere to proper milk discard period will result in violative milk residues. SPECTRAMAST LC requires a 72-hour milk discard period and a two-day pre-slaughter withdrawal period following the last treatment. As with all drugs, SPECTRAMAST LC should not be used in animals found to be hypersensitive to the product. 1.17.2012